Pathological glial reactions in neurodegenerative disorders: Prospects for future therapeutics

Expert Review of Neurotherapeutics

Volumn 3, Issue 3, 2003, Pages 279-287

  Schubert, Peter ^a   Ferroni, Stefano ^b  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Calcium signalling; IL 1 inhibition; Protective adenosine; Reactive astrocytes; Reactive microglia; Receptor cross talk; Reinforced cAMP signalling; Reinforced cGMP signalling; TNF inhibition; Upregulated glia reaction

Indexed keywords

ADENOSINE; AMYLOID BETA PROTEIN;

ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL FUNCTION; DEGENERATIVE DISEASE; GLIA CELL; HOMEOSTASIS; HUMAN; IMMUNOCOMPETENT CELL; MICROGLIA; NERVE CELL LESION; OXIDATIVE STRESS; SECOND MESSENGER; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; TREATMENT PLANNING;

EID: 0038137583     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.3.279     Document Type: Article

References (49)

1. Reed JC. Apoptosis-based therapies. Nat. Rev. Drug Disc. 11, 111-121 (2002).
2. Mattson MP. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 1, 120-129 (2000).
3. Graeber MB, Moran LB. Mechanisms of cell death in neurodegenerative diseases: fiction and facts. Brain Pathol. 12, 385-390 (2002).
4. Hirsch EC, Hunot S, Faucheux B et al. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov. Disord. 14, 383-385 (1999).
5. Giasson BE, Lee VM. Parkin and the molecular pathways of Parkinson's disease. Neuron 31, 885-888 (2001).
6. Lin S, Zhang Y, Dodel R, Farlow MR, Paul SM, Du Y. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAPK in rat cerebellar granule neurons. Neurosci. Lett 315, 61-64 (2001).
7. Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of evidence. Neuropathol. Appl. Neurobiol. 27, 257-274 (2001).
8. Antuono P, Beyer J. The bourdon of dementia. A medical and research perspective. Theor. Med. Bioeth. 20, 3-13 (1999).
9. Irizarry MC, Hyman BT. Alzheimer's disease therapeutics. J. Neuropathol. Exp. Neurol. 60, 923-928 (2001).
10. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study. Int. J. Geriatr. Pychiatry 14, 135-146 (1999).
11. Mattson MP, Duan W, Pedersen WA, Culmsee C. Neurodegenerative disorders and ischemic brain diseases. Apoptosis 6, 69-81 (2001).
12. Breitner JC. Epidemiologic clues to the causes and routes to prevention of Alzheimer's disease. J. Neural Transm. Suppl. 59, 251-254 (2000).
13. Mackenzie IR, Munoz DG. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 50, 986-990 (1998).
14. Sasaki A, Yamaguchi H, Ogawa A, Sugihara S, Nakazato Y. Microglial activation in early stages of amyloid-β protein deposition. Acta Neuropathol. 94, 316-322 (1997).
15. Schubert P, Rudolphi K. Interfering with the pathologic activation of microglial cells and astrocytes in dementia. Alz. Dis. Ass. Disorders 12, 21-28 (1998).
16. Schubert P, Ogata T, Rudolphi K, Marchini C, McRae A, Ferroni S. Support of homeostatic glial cell signalling: a novel therapeutic approach by propentofylline. Ann. NY Acad. Sci. 826, 337-347 (1997).
17. Kittner B, Roessner M, Rother M. Clinical trials in dementia. Ann. NY Acad. Sci. 826, 307-316 (1997).
18. Jantzen PT, Konnor KE, DiCarlo G et al. Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus preseniline-1 transgenic mice. J. Neurosci. 22, 2246-2254 (2002). Good introduction to the problem of reactive glial cell function (good or bad, or both?).
19. Raivich G, Bohatschek M, Kloss et al. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res. Rev. 30, 77-105 (1999). The activation state of reactive microglia, which determines their potentially neurotoxic power, is reflected by the graded expression of different cell-surface markers.
20. Haydon PG. Glia: listening and talking to the synapse. Nat. Rev. Neurosci. 2, 185-193 (2001). Reviews the evolving essential role of astrocytes for physiological brain function and their active participation in synaptic transmission.
21. Bezzi P, Domercq M, Brambilla L et al. CXCR4-activated astrocyte glutamate release via TNF-α: amplification by microglia triggers neurotoxicity. Nat. Neurosci. 4, 702-710 (2001). Illustration of the dangerous TNF-α mediated (and astrocyte-linked) mechanisms, which allow strengthening of synaptic efficacy but may also turn into a damaging pathomechanism.
22. Aschner M. Astrocytes as mediators of immune and inflammatory responses in the CNS. Neurotoxicology 19, 269-289 (1998).
23. Giullian D. A strategy for identifying immunosuppressive therapies for Alzheimer's disease. Alzheimer's disease and Associated Disorder 12(Suppl. 2), 7-14 (1998).
24. Vincent VAM, Tilders FJH, van Dam AM. Inhibition of endotoxin-induced oxide synthase production in microglial cells by the presence of astroglial cells: a role for transforming growth factor β. Glia 19, 190-198 (1997).
25. Meda L, Baron P, Scarlato G. Glial activation in Alzheimer's disease: the role of Aβ and its associated proteins. Neurobiol. Aging 22, 885-893 (2001). Evaluation of the escalating activation of microglia and astrocytes by toxic β-amyloid.
26. Schubert P, Morino T, Miyazaki H et al. Cascading glia reactions: a common pathomechanism and its differentiated control by cyclic nucleotide signaling. Ann. NY Acad. Sci. 903, 24-34 (2000).
27. Schubert P, Ogata T, Marchini C, Ferroni S. Glia-related pathomechanisms in Alzheimer's disease: a therapeutic target? Mech. Aging Develop. 123, 47-57 (2001). Evaluation of possible modes of protection by influencing (potentially neurotoxic) reactive glial cell functions at the second messenger level. Here, the action of the cell modulator, adenosine, which influences the generation and interaction of the second messengers calcium and cyclic AMP, may be a promising target for pharmacological intervention.
28. Hewett SJ, Csernansky CA, Choi DW. Selective potentiation of NMDA induced neuronal injury following induction of astrocytic iNOS. Neuron 13, 487-494 (1994). Pioneering paper that suggests a possible pathogenic role of reactive astrocytes to oxidative neuronal damage.
29. LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nature Rev. Neurosci. 3, 862-872 (2002).
30. Haskew RE, Mongin AA, Kimelberg HK. Peroxynitrite enhances astrocytic volume-sensitive excitatory amino acid release via a src tyrosine kinase-dependent mechanism J. Neurochem. 82, 903-912 (2002).
31. Akama KT, van Eldik LJ. β-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1β and tumor necrosis factor-α dependent and involves a TNF-α. receptor-associated factor and NFkB inducing kinase-dependent signaling mechanism. J. Biol. Chem. 275, 7918-7924 (2000).
32. Ishii K, Muelhauser F, Liebl U, Beyreuther K. Subacute NO generation induced by Alzheimer's β-amyloid in the living brain: reversed by inhibition of the inducible NO synthase. FASEB J. 14, 1485-1489 (2000).
33. Ma J, Yee A, Brewer HB, Das S, Potter H. Amyloid associated proteins α-1-antichymotrypsin and apolipoprotein-E assembly of β-protein into filaments. Nature 372, 92-94 (1994). Pioneering paper showing that specific proteins, which can be formed by reactive astrocytes, aggravate β-amyloid toxicity.
34. Small DH, Mok SS, Bornstein JC. Alzheimer's disease and Aβ toxicity: from top to bottom. Nat. Rev. Neurosci. 2, 595-598 (2001). It is interesting that an impairment of synaptic function is proposed as the major pathomechanism responsible for the generation of dementia.
35. Selbie LA, Hill S. G-protein coupled receptor crosstalk: the fine-tuning of multiple receptor-signalling pathways. TIPS 19, 87-93 (1998). The evolving sophisticated signaling cross-talk may be a promising target for future therapy.
36. Ongini E, Schubert P. Neuroprotection induced by stimulating A1 or blocking A2a adenosine receptors: an apparent paradox. Drug Devel. Res. 45, 387-393 (1998).
37. Sebastiao A, Ribieiro J. Fine tuning neuromodulation by adenosine. Trends Pharmacol. Sci. 21, 341-361 (2000). Recently reviewed the fine-tuning modulation of various cell functions by adenosine.
38. Moreau JL, Huber G. Central adenosine A (A2A) receptors: an overview. Brain Res. Rev. 31, 65-82 (1999).
39. Si Q, Nakamura Y, Ogata T, Kataoka K, Schubert P. Differential regulation of microglial activation by propentofylline via cAMP signaling. Brain Res. 812, 97-104 (1998).
40. Ogata T, Kohgami S, Okumura H et al. Nitric oxide-induced neurotoxicity is inhibited by propentofylline via cyclic GMP elevation. Neurobiol. Aging 19, 255 (1998).
41. Takuma K, Phuagphong P, Lee E, Mori K, Baba A, Matsuda T. Anti-apoptotic effect of cGMP in cultured astrocytes: inhibition by cGMP-dependent protein kinase of mitochondrial permeability transition pore. J. Biol. Chem. 276, 48093-48099 (2001).
42. Lee SF, Chao MV. Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl Acad. Sci. 98, 3555-3560 (2001). Very interesting idea of the newly evolving capability of adenosine to mediate a cross-talk between different signaling pathways at the second messenger level. Reinforcement of this adenosine action may provide a chance to recover pathologically impaired pathways, such as NGF producing neurotrophic pathways.
43. Neumann H, Misgeld T, Matsauro K, Wekerle H. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc. Natl. Acad. Sci. (USA) 95, 5779-5784 (1998).
44. 2 adenosine receptor cooperation. Eur. J. Neurosci. 8, 1124-1131 (1996). Experimental evaluation of the adenosine mediated interaction between the second messengers calcium and cAMP in cultured astrocytes.
45. Ferroni S, Marchini C, Ogata T, Schubert P. Recovery of deficient cholinergic calcium signaling by adenosine in cultured rat cortical astrocytes. J. Neurosci. Res. 68, 615-621 (2002). A further example of the newly evolving capability of adenosine to mediate a cross-talk between different signaling pathways at the second messenger level. Reinforcement of this adenosine action may provide a chance to recover pathologically impaired pathways, such as the deficient muscarinic signaling in Alzheimer's disease.
46. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Ann. Rev. Immunol. 18, 217-242 (2000).
47. Weggen S, Eriksen JL, Das P et al. A subset of NSAIDs lower amyloidogenic Abeta42 independent of cyclooxygenase activity. Nature 414, 159-160 (2001). An evolving possibility of pharmacological interference with β-amyloid toxicity.
48. McGeer P, McGeer EG. Inflammation, autotoxicity and Alzheimer's disease. Neurobiol. Aging 22, 799-809 (2001). Highly authentic view of the presumed significance of reactive microglia for neuronal damage.
49. Bin L, Jau-Shyong H. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J PET 304, 1-7 (2003). Recently reviewed the presumed significance of reactive microglia for neuronal damage.